Glenmark Pharmaceuticals has received the Establishment Inspection Report (EIR) from the U.S. Food and Drug Administration (USFDA) for its formulations manufacturing facility in Goa, India with a Voluntary Action Indicated (VAI) status. The inspection was conducted at the Company’s manufacturing facility from June 22, 2026 to June 30, 2026.
Glenmark Pharmaceuticals is a global research-led pharmaceutical company with presence across Generics, Specialty and OTC business with operations in over 50 countries.
